Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New India Drug Price Caps Narrowed To Three Options

This article was originally published in PharmAsia News

Executive Summary

Indian price regulators are considering three types of maximum charges for two-thirds of pharmaceuticals not already controlled. One possibility is to cap the trade margin at 300 percent of the manufacturer's price instead of the current 2,900 percent. Another option considered is setting the cap at 50 percent or 70 percent of the leading brand in each category, an option opposed by the National Pharmaceutical Pricing Authority. A third option would set the top price at 15 percent of the printed maximum retail price, 35 percent for retailers. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel